Effects of Inhaled Salbutamol Versus 0.9% Normal Saline on Duration of Hospital Stay in Transiennt Tachypnea of Newborn
DOI:
https://doi.org/10.54112/bcsrj.v6i6.1801Keywords:
Beta-agonist, Hospital stay, Inhaled salbutamol, Neonates, Oxygen therapy, Randomized controlled trial, Transient tachypnea of the newborn (TTN)Abstract
Transient tachypnea of the newborn (TTN) is a common cause of respiratory distress in neonates, often requiring prolonged hospitalization and oxygen therapy. Enhancing lung fluid absorption using beta-agonists like salbutamol may reduce disease duration and hospital stay. Objective: To compare the effects of inhaled salbutamol versus 0.9% normal saline on the duration of hospital stay and oxygen therapy in neonates diagnosed with TTN. Methods: This randomized controlled trial was conducted at the department of Pediatric Medicine in the Ibn-e-Siena Hospital Multan from November 2023 to November 2024 and included 60 term or late preterm neonates with clinical and radiographic evidence of TTN. Participants were randomly assigned to receive either a single dose of inhaled salbutamol (0.15 ml/kg in 4 ml saline) or 4 ml of 0.9% saline via nebulization. Respiratory parameters were monitored, and the primary outcome was duration of hospital stay. Secondary outcomes included duration of oxygen therapy and improvements in respiratory rate and oxygen saturation. Data were analyzed using SPSS version 23.0, and an independent t-test was applied. A p-value ≤ 0.05 was considered statistically significant. Results: The mean duration of oxygen therapy was significantly lower in the salbutamol group (7.13 ± 2.16 hours) compared to the control group (11.67 ± 5.97 hours; p < 0.001). The mean duration of hospital stay was also shorter in the salbutamol group (3.33 ± 1.16 days) than in the control group (4.90 ± 1.49 days), although the difference was not statistically significant (p = 0.229). Baseline characteristics such as gestational age, birth weight, and maternal age were comparable between the groups. Conclusion: Inhaled salbutamol is effective in reducing the duration of oxygen therapy in neonates with TTN. Although not statistically significant, it may also contribute to shorter hospital stays. This intervention may be particularly beneficial in resource-constrained settings. Further larger-scale studies are warranted.
Downloads
References
Dani C, Corsini I, Poggi C. Lung ultrasound in neonatology: Usefulness in clinical daily practice. J Matern Fetal Neonatal Med. 2019;32(22):3860–8. https://doi.org/10.1080/14767058.2018.1471397
Kasap B, Dilli D, Beken S, et al. Role of beta-agonist salbutamol in the treatment of transient tachypnea of the newborn. PediatrPulmonol. 2018;53(5):637–43. https://doi.org/10.1002/ppul.23971
Anantasit N, Nuntnarumit P, Termritthikun P, et al. Efficacy of nebulized salbutamol in transient tachypnea of the newborn: A randomized controlled trial. PediatrPulmonol. 2021;56(2):434–40. https://doi.org/10.1002/ppul.25104
Rizvi RM, Hatcher J, Jehan I, Qureshi R. Maternal and newborn care practices in Pakistan: A review of existing evidence. J Pak Med Assoc. 2017;67(3):421–9. https://jpma.org.pk/article-details/8126
Li AM, Chan D, Wong E, et al. Randomized controlled study of inhaled beta-agonist in the treatment of transient tachypnea of the newborn. PediatrPulmonol. 2018;53(5):548–54. https://doi.org/10.1002/ppul.23900
Helve O, Pitkanen OM, Andersson S. Metabolic and respiratory adaptation in neonates: Role of beta2-agonists in lung fluid absorption. Neonatology. 2019;115(1):66–72. https://doi.org/10.1159/000493282
Ozkiraz S, Gokmen Z, Beyazit Z, et al. Nebulized salbutamol therapy in newborns with TTN: A double-blind, placebo-controlled trial. J Trop Pediatr. 2020;66(2):172–9. https://doi.org/10.1093/tropej/fmz048
Abdel Hady H, Hany H, Kassem R, et al. Efficacy of inhaled beta-agonists in the treatment of TTN: A randomized clinical study. Am J Perinatol. 2020;37(1):62–7. https://doi.org/10.1055/s-0039-1688482
Kasap B, Dilli D, Beken S, et al. Role of beta-agonist salbutamol in the treatment of transient tachypnea of the newborn. PediatrPulmonol. 2018;53(5):637–43. https://doi.org/10.1002/ppul.23971
Helve O, Pitkänen OM, Andersson S. Role of beta-adrenergic agonists in lung fluid absorption in neonates. Neonatology. 2019;115(1):66–72. https://doi.org/10.1159/000493282
Anantasit N, Nuntnarumit P, Termritthikun P, et al. Efficacy of nebulized salbutamol in transient tachypnea of the newborn: A randomized controlled trial. PediatrPulmonol. 2021;56(2):434–40. https://doi.org/10.1002/ppul.25104
Ozkiraz S, Gokmen Z, Beyazit Z, et al. Nebulized salbutamol therapy in newborns with TTN: A double-blind, placebo-controlled trial. J Trop Pediatr. 2020;66(2):172–9. https://doi.org/10.1093/tropej/fmz048
Abdel Hady H, Hany H, Kassem R, et al. Efficacy of inhaled beta-agonists in the treatment of TTN: A randomized clinical study. Am J Perinatol. 2020;37(1):62–7. https://doi.org/10.1055/s-0039-1688482
Li AM, Chan D, Wong E, et al. Randomized controlled study of inhaled beta-agonist in the treatment of transient tachypnea of the newborn. PediatrPulmonol. 2018;53(5):548–54. https://doi.org/10.1002/ppul.239005
Downloads
Published
How to Cite
Issue
Section
License
Copyright (c) 2025 Ayesha Anam, Asif Javeed, Sidra Shahid, Saima Manzoor

This work is licensed under a Creative Commons Attribution-NonCommercial 4.0 International License.